DAPPER demonstrates 98% feasibility of daily adaptive salvage SABR after prostatectomy

In 50 patients, daily adaptive salvage SABR improved prostate fossa and nodal boost coverage while reducing bowel and rectal exposure.

KEY POINTS

  • The prospective, single-center DAPPER phase II study (NCT05830838) enrolled 50 patients with biochemical recurrence after radical prostatectomy between August 2023 and March 2024. Patients received CBCT-guided online adaptive SABR in five fractions over approximately two weeks, delivered using the Varian Ethos platform. The study evaluated feasibility, treatment duration, target coverage, and OAR dosimetry across 250 treatment fractions, including patients receiving prostate fossa irradiation with or without pelvic lymph nodes and integrated boosts.
  • Treatment delivered 32 Gy in five fractions to the prostate fossa, with optional 25 Gy in five fractions to elective pelvic lymph nodes. Radiographically detected disease received simultaneous integrated boosts to 35.5 Gy in the prostate fossa or 37.5 Gy in involved pelvic nodes. All targets used 3-mm PTV margins. Pelvic lymph nodes were treated in 40/50 patients (80%), while 20 patients (40%) received a fossa boost and 16 (32%) received an involved-nodal boost.
  • The prespecified feasibility endpoint was achieved in 246/250 fractions (98%), exceeding the required 90% completion threshold. The four fractions not meeting the formal feasibility definition occurred in one patient because substantial anatomical changes prevented calculation of the scheduled reference plan; importantly, the adaptive plans were successfully generated and delivered. Adaptive plans were selected for 222/250 fractions (89%), demonstrating that daily anatomical variation frequently justified reoptimization.
  • Daily adaptation significantly improved target coverage, especially for involved pelvic lymph nodes. Mean PTV V95% for the 37.5-Gy nodal boost increased from 75.4% with scheduled plans to 94.6% with adaptive plans. Target coverage improved significantly across all evaluated PTVs, and the adaptive plans met the study's priority target-coverage objective of V95% >92.5% on average. Improvements were particularly relevant for smaller boost volumes affected by independent motion of the prostate fossa and pelvic nodal anatomy.
  • Adaptation substantially reduced bowel and rectal dose-volume exposure. Mean bowel V25Gy decreased from 16.3 to 2.6 cm³, while rectal V25Gy decreased from 15.4 to 10.9 cm³, allowing the adapted plans to meet the institutional rectal V25Gy objective of <15 cm³. In contrast, mean bladder V25Gy increased from 26.5 to 33.5 cm³, although both scheduled and adapted plans remained within the protocol's <50 cm³ bladder constraint. This illustrates that improved target coverage may require accepting higher doses to selected OARs.
  • The adaptive workflow required substantial treatment time. Mean contouring duration was 27 ± 9 minutes, plan generation and review required approximately 7 minutes, and treatment delivery approximately 14 minutes. Mean total treatment time was 50 ± 15 minutes, increasing from 38 minutes for prostate fossa treatment alone to 53 minutes when pelvic nodes were included (p<0.001). Treatment duration also increased with the number of target volumes, reaching approximately 62 minutes for four targets, compared with 33 minutes for one target.
  • The reported advantages are per-fraction planning outcomes, not accumulated delivered-dose or clinical results. Intrafraction motion, anatomical changes between adaptation and delivery, and cumulative deformable dose accumulation were not evaluated. The study provides no mature biochemical control, long-term GU/GI toxicity, or patient-reported quality-of-life results, and the single-institution staffing-intensive workflow may not generalize to other departments.

CLINICAL TAKEAWAY

Daily CBCT-guided adaptive SABR after prostatectomy appears feasible for complex salvage treatments incorporating pelvic nodes and simultaneous integrated boosts, improving target coverage while reducing selected bowel and rectal dose metrics. These prospective data support continued investigation of adaptive ultrahypofractionated salvage treatment, but they do not establish clinical superiority or long-term safety compared with conventional or moderately hypofractionated salvage radiotherapy.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction